3-O-Methyldopa administration does not alter fluorodopa transport into the brain

Mark Guttman, Gabriel Léger, Jesse M. Cedarbaum, Avinoam Reches, William Woodward, Alan Evans, Mirko Diksic, Albert Gjedde

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 ± 4 μM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)638-643
Number of pages6
JournalAnnals of Neurology
Volume31
Issue number6
StatePublished - Jun 1992

Fingerprint

Levodopa
Brain
Macaca fascicularis
Positron-Emission Tomography
Parkinson Disease
3-O-methyl-DOPA
fluorodopa F 18
Electrons
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Guttman, M., Léger, G., Cedarbaum, J. M., Reches, A., Woodward, W., Evans, A., ... Gjedde, A. (1992). 3-O-Methyldopa administration does not alter fluorodopa transport into the brain. Annals of Neurology, 31(6), 638-643.

3-O-Methyldopa administration does not alter fluorodopa transport into the brain. / Guttman, Mark; Léger, Gabriel; Cedarbaum, Jesse M.; Reches, Avinoam; Woodward, William; Evans, Alan; Diksic, Mirko; Gjedde, Albert.

In: Annals of Neurology, Vol. 31, No. 6, 06.1992, p. 638-643.

Research output: Contribution to journalArticle

Guttman, M, Léger, G, Cedarbaum, JM, Reches, A, Woodward, W, Evans, A, Diksic, M & Gjedde, A 1992, '3-O-Methyldopa administration does not alter fluorodopa transport into the brain', Annals of Neurology, vol. 31, no. 6, pp. 638-643.
Guttman M, Léger G, Cedarbaum JM, Reches A, Woodward W, Evans A et al. 3-O-Methyldopa administration does not alter fluorodopa transport into the brain. Annals of Neurology. 1992 Jun;31(6):638-643.
Guttman, Mark ; Léger, Gabriel ; Cedarbaum, Jesse M. ; Reches, Avinoam ; Woodward, William ; Evans, Alan ; Diksic, Mirko ; Gjedde, Albert. / 3-O-Methyldopa administration does not alter fluorodopa transport into the brain. In: Annals of Neurology. 1992 ; Vol. 31, No. 6. pp. 638-643.
@article{8167045cc6e04593b300ac10ee0bd96b,
title = "3-O-Methyldopa administration does not alter fluorodopa transport into the brain",
abstract = "To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 ± 4 μM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.",
author = "Mark Guttman and Gabriel L{\'e}ger and Cedarbaum, {Jesse M.} and Avinoam Reches and William Woodward and Alan Evans and Mirko Diksic and Albert Gjedde",
year = "1992",
month = "6",
language = "English (US)",
volume = "31",
pages = "638--643",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - 3-O-Methyldopa administration does not alter fluorodopa transport into the brain

AU - Guttman, Mark

AU - Léger, Gabriel

AU - Cedarbaum, Jesse M.

AU - Reches, Avinoam

AU - Woodward, William

AU - Evans, Alan

AU - Diksic, Mirko

AU - Gjedde, Albert

PY - 1992/6

Y1 - 1992/6

N2 - To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 ± 4 μM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.

AB - To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 ± 4 μM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0026724717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026724717&partnerID=8YFLogxK

M3 - Article

C2 - 1514775

AN - SCOPUS:0026724717

VL - 31

SP - 638

EP - 643

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -